
    
      If the participant fulfills the initial eligibility criteria, the patient will be randomized
      to 1 of the active treatment groups or placebo. During the treatment period, patients will
      receive study medication once daily for 8 days. Patients will undergo scintigraphic
      assessment of gastric, small bowel and colonic transit of solids over the 48-hour period.

      Patients will be males or females, 18 through 65 years of age with a body mass index (BMI) of
      19 through 40 kg/m2, with Chronic Constipation or Functional Constipation and no evidence of
      evacuation disorder as assessed by the Investigator and meet all the inclusion criteria and
      none of the exclusion criteria.
    
  